Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...

When the concept of RNA interference was first introduced in the early 2000s, it raised the tantalizing possibility of using RNA molecules to modify human gene expression. 1 Since then, a wide range ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 million into its biomanufacturing plant in Norton.

Arrowhead Pharmaceuticals, Inc. today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar ? ARO-INHBE and ARO-ALK7 Interim Clinical Data ? January 6, ...

A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

Alnylam Pharmaceuticals is expanding its Norton facility with a $250 million investment to enhance RNAi therapeutic ...

Ten of the twelve former Food and Drug Administration (FDA) commissioners and acting commissioners opposed to the Trump ...

Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 ...

The Nasdaq-100 is reconstituted each year in December, timed to coincide with the quadruple witch expiration on the Friday of ...

Silence Therapeutics ( ($SLN) ) just unveiled an announcement. On December 18, 2025, Silence Therapeutics plc appointed its Executive Vice ...